The development of drugs to treat some of the world’s most deadly viruses is a primary area of focus by the pharmaceutical community during the last 20 years. There are dozens of antiviral drugs currently approved for use and many times more in development. The ability to easily and quickly follow the impact of a given therapy on viral concentration provides significant advantages over traditional approaches that slow down the pace of research by days or weeks. To learn more, email us at email@example.com.
White Papers & Case Studies
“We are using the Virus Counter at multiple sites…and by now have tested it on quite a large number of viruses within Sanofi Pasteur, and within the Sanofi Group also within Merial and VaxDesign in Florida.”